| TOKAI PHARMACEUTICALS, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110319369 | COMBINATION OF A 17 ALPHA-HYDROXYLASE/C17, 20-LYASE INHIBITOR WITH AN ADDITIONAL THERAPEUTIC AGENT - The invention describes methods of treating cancer in which a therapeutically-effective amount of a 17α-hydroxylase/C | 12-29-2011 |
| 20110312924 | NOVEL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS - Steroidal C-17 nitrogen-containing heterocycles of Formula I: | 12-22-2011 |
| 20110312916 | NOVEL PRODRUGS OF STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS - Prodrugs of C-17-heterocyclic-steroidal drugs providing improved oral bioavailability and pharmacokinetics are described. The drugs are inhibitors of human CYP 17 enzyme, as well as potent antagonists of both wild type and mutant androgen receptors (AR), and are useful for the treatment of urogenital and/or androgen-related cancers, diseases and/or conditions, such as human prostate cancer, breast cancer, and prostate hyperplasia. The disclosure describes methods of synthesizing and using the prodrugs in cancer therapy. | 12-22-2011 |
| 20110034428 | Treatment of Prostate Cancer - Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. The present invention provides therapies and therapeutic regimens for the treatment of prostate cancer. | 02-10-2011 |
